Loading...

curasan

DB:CUR
Snowflake Description

Fair value with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CUR
DB
€9M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

curasan AG, together with its subsidiaries, develops, produces, and markets biomaterials and medical devices for bone and tissue regeneration worldwide. The last earnings update was 245 days ago. More info.


Add to Portfolio Compare Print
  • curasan has significant price volatility in the past 3 months.
CUR Share Price and Events
7 Day Returns
10.9%
DB:CUR
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-54.9%
DB:CUR
-5.6%
DE Biotechs
-4.5%
DE Market
CUR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
curasan (CUR) 10.9% 21.4% -8.9% -54.9% -53.2% -72%
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • CUR underperformed the Biotechs industry which returned -5.6% over the past year.
  • CUR underperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
CUR
Industry
5yr Volatility vs Market

CUR Value

 Is curasan undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of curasan to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for curasan.

DB:CUR Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:CUR
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 30%) (7.94%))
1.358
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.36
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.358 * 5.96%)
8.32%

Discounted Cash Flow Calculation for DB:CUR using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for curasan is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:CUR DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 8.32%)
2019 -2.41 Analyst x2 -2.22
2020 -1.57 Analyst x2 -1.34
2021 -0.53 Analyst x1 -0.42
2022 0.05 Analyst x1 0.03
2023 0.59 Analyst x1 0.40
2024 1.02 Est @ 72.39% 0.63
2025 1.54 Est @ 50.74% 0.88
2026 2.09 Est @ 35.59% 1.10
2027 2.61 Est @ 24.98% 1.27
2028 3.07 Est @ 17.55% 1.38
Present value of next 10 years cash flows €1.72
DB:CUR DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €3.07 × (1 + 0.23%) ÷ (8.32% – 0.23%)
€38.03
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €38.03 ÷ (1 + 8.32%)10
€17.10
DB:CUR Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €1.72 + €17.10
€18.82
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €18.82 / 18.38
€1.02
DB:CUR Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:CUR represents 1.03869x of XTRA:CUR
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.03869x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 1.02 x 1.03869
€1.06
Value per share (EUR) From above. €1.06
Current discount Discount to share price of €0.51
= -1 x (€0.51 - €1.06) / €1.06
52%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price curasan is available for.
Intrinsic value
>50%
Share price is €0.51 vs Future cash flow value of €1.06
Current Discount Checks
For curasan to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • curasan's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • curasan's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for curasan's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are curasan's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:CUR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €-0.31
XTRA:CUR Share Price ** XTRA (2019-04-25) in EUR €0.49
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of curasan.

DB:CUR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= XTRA:CUR Share Price ÷ EPS (both in EUR)

= 0.49 ÷ -0.31

-1.58x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • curasan is loss making, we can't compare its value to the Europe Biotechs industry average.
  • curasan is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does curasan's expected growth come at a high price?
Raw Data
DB:CUR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.58x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
37.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for curasan, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on curasan's assets?
Raw Data
DB:CUR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €0.54
XTRA:CUR Share Price * XTRA (2019-04-25) in EUR €0.49
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:CUR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= XTRA:CUR Share Price ÷ Book Value per Share (both in EUR)

= 0.49 ÷ 0.54

0.9x

* Primary Listing of curasan.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • curasan is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess curasan's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. curasan has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CUR Future Performance

 How is curasan expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
37.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is curasan expected to grow at an attractive rate?
  • Unable to compare curasan's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare curasan's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • curasan's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:CUR Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:CUR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 37.4%
DB:CUR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 11.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:CUR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:CUR Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 11 2
2022-12-31 10 2
2021-12-31 9 0 -1 2
2020-12-31 8 -1 -2 2
2019-12-31 7 -2 -3 2
2018-12-31 6 -3 -5 2
DB:CUR Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 7 -3 -3
2018-03-31 7 -3 -4
2017-12-31 7 -3 -4
2017-09-30 7 -1 -3
2017-06-30 7 -1 -3
2017-03-31 7 -2 -2
2016-12-31 7 -2 -2
2016-09-30 6 0 -3
2016-06-30 6 -1 -3
2016-03-31 6 2 1
2015-12-31 6 2 1
2015-09-30 6 0 2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • curasan is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • curasan's revenue is expected to grow by 11.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:CUR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from curasan Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CUR Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 -0.06 -0.06 -0.06 1.00
2020-12-31 -0.09 -0.07 -0.11 2.00
2019-12-31 -0.15 -0.14 -0.15 2.00
2018-12-31 -0.27 -0.26 -0.27 2.00
DB:CUR Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 -0.31
2018-03-31 -0.33
2017-12-31 -0.33
2017-09-30 -0.26
2017-06-30 -0.21
2017-03-31 -0.19
2016-12-31 -0.21
2016-09-30 -0.34
2016-06-30 -0.36
2016-03-31 0.12
2015-12-31 0.15
2015-09-30 0.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if curasan will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess curasan's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
curasan has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CUR Past Performance

  How has curasan performed over the past 5 years?

  • curasan's last earnings update was 245 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare curasan's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • curasan does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare curasan's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare curasan's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
curasan's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from curasan Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CUR Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 7.04 -3.48 3.79
2018-03-31 6.84 -4.29 3.87
2017-12-31 6.80 -4.00 3.73
2017-09-30 6.72 -2.89 3.71
2017-06-30 6.77 -2.84 3.71
2017-03-31 6.78 -2.04 3.64
2016-12-31 6.50 -2.09 3.61
2016-09-30 5.90 -3.33 3.43
2016-06-30 5.76 -3.36 3.37
2016-03-31 5.53 1.08 3.37
2015-12-31 5.62 1.33 3.26
2015-09-30 5.89 1.60 3.12
2015-06-30 6.01 2.16 2.92
2015-03-31 6.11 -1.76 2.66
2014-12-31 5.99 -1.83 2.72
2014-09-30 6.23 -1.54 3.11
2014-06-30 6.52 -1.84 3.27
2014-03-31 6.23 -1.92 3.43
2013-12-31 5.83 -1.99 3.43
2013-09-30 4.94 -2.48 3.46
2013-06-30 4.00 -2.57 3.42
2013-03-31 3.66 -2.98 3.31
2012-12-31 3.23 -3.47 3.34
2012-09-30 3.65 -2.52 3.49
2012-06-30 3.33 -2.54 3.45

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if curasan has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if curasan has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if curasan improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess curasan's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
curasan has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CUR Health

 How is curasan's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up curasan's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • curasan is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • curasan's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of curasan's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 8.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from curasan Company Filings, last reported 9 months ago.

DB:CUR Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 8.45 0.72 0.47
2018-03-31 8.45 0.72 0.47
2017-12-31 9.94 0.27 2.29
2017-09-30 6.75 0.70 0.59
2017-06-30 7.03 0.43 0.21
2017-03-31 8.52 0.03 0.21
2016-12-31 8.95 0.00 1.01
2016-09-30 7.93 0.00 0.27
2016-06-30 8.76 0.00 0.78
2016-03-31 8.38 0.01 0.52
2015-12-31 8.84 0.01 1.59
2015-09-30 10.36 0.02 2.46
2015-06-30 11.20 0.03 3.71
2015-03-31 6.42 0.04 1.06
2014-12-31 6.55 0.05 1.55
2014-09-30 5.99 0.08 0.23
2014-06-30 6.32 0.18 0.43
2014-03-31 6.56 0.17 0.41
2013-12-31 6.89 0.08 0.78
2013-09-30 7.55 0.06 0.59
2013-06-30 8.16 0.06 1.39
2013-03-31 6.98 0.07 2.19
2012-12-31 7.38 0.12 3.01
2012-09-30 8.52 0.10 3.45
2012-06-30 9.26 0.10 4.67
  • curasan's level of debt (8.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.7% vs 8.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • curasan has less than a year of cash runway based on current free cash flow.
  • curasan has less than a year of cash runway if free cash flow continues to grow at historical rates of 98.1% each year.
X
Financial health checks
We assess curasan's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. curasan has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CUR Dividends

 What is curasan's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from curasan dividends.
If you bought €2,000 of curasan shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate curasan's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate curasan's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:CUR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:CUR Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31
DB:CUR Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2011-04-14 0.160 5.354

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as curasan has not reported any payouts.
  • Unable to verify if curasan's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of curasan's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as curasan has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess curasan's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can curasan afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. curasan has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CUR Management

 What is the CEO of curasan's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Schlenk
COMPENSATION €264,000
TENURE AS CEO 5.3 years
CEO Bio

Mr. Michael Schlenk, MBA, has been the Chief Executive Officer of Curasan AG since 2014 and has been its Chairman of the Management Board since October 07, 2014. Mr. Schlenk has fifteen years of Big Pharma experience. Mr. Schlenk served as the Chief Executive Officer at Centogene AG since January 2011. He served as the Chief Executive Officer at ProBioGen AG since October 2003. He served as General Manager at Abbott in Austria and Brazil and held various executive positions in the areas of strategy/country management in Asia-Pacific countries, as well as Sales and Marketing at Sandoz Pharma (now Novartis). He worked as a Management Consultant in the area of technology transfer. He has over 25 years in the pharmaceutical industry, more than 20 years experience as CEO, Business Angel and active investor in the growing biotech-market. He served as Strategic Consultant, Marketing Manager, Area Manager, General Manager and President of Novartis and Abbott. He served as Chief Executive Officer of ProBioGen AG for 7 years and led it to sustained profitability and prepared it for the trade sale. Since 2003, he develops and invests as business angel in young IT and Life Science companies. He was member of various supervisory boards. In January 2011, he invested and was named Chief Executive Officer (CEO) of the Centogene AG and has systematic marketing through international partnerships and collaborations and a professional development. ProBioGen AG under his leadership achieved numerous awards for fast growth and technological excellence: Deloitte Fast Forward Award (2 times), Step Award (FAZ German news paper), BMBF and Peta. He earned a Diplom-Kaufmann degree from University Hamburg, Germany and an MBA from University Bradford Management Centre, U.K. He also completed MSc (Econ).

CEO Compensation
  • Michael's compensation has increased whilst company is loss making.
  • Michael's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the curasan management team in years:

4
Average Tenure
  • The tenure for the curasan management team is about average.
Management Team

Michael Schlenk

TITLE
Chairman of the Management Board & CEO
COMPENSATION
€264K
TENURE
5.3 yrs

Fabian Peters

TITLE
Technical Director
AGE
48

Ingo Middelmenne

TITLE
Head of Investor Relations

Andrea Weidner

TITLE
Head of Corporate Communications

Gregor Siebert

TITLE
Head of Marketing & Sales
TENURE
4 yrs

Shane Ray

TITLE
President of USA
TENURE
2.9 yrs
Board of Directors

Detlef Wennigsen

TITLE
Chairman of the Supervisory Board
COMPENSATION
€32K

Isabella de Krassny

TITLE
Deputy Chairman of the Supervisory Board
AGE
60

Tomas Kahn

TITLE
Member of the Supervisory Board
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess curasan's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. curasan has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CUR News

Simply Wall St News

CUR Company Info

Description

curasan AG, together with its subsidiaries, develops, produces, and markets biomaterials and medical devices for bone and tissue regeneration worldwide. The company specializes in offering biomimetic bone grafting materials, which are used in traumatology, spine surgery, orthopedics, and dental implantology. Its products include CERASORB, a bone replacement material; stypro, a sterile and porous sponge for hemostasis; Curavisc, a hyaluronic acid for the treatment of osteoarthritis; Osbone, a synthetic open–cell cancellous bone graft material for filling bone defects and augmentation of the atrophied alveolar ridge; foils and membranes for use in dental and oral surgeries; and accessories, such as fixation systems for use in bone augmentation surgery. curasan AG was founded in 1988 and is headquartered in Kleinostheim, Germany.

Details
Name: curasan AG
CUR
Exchange: DB
Founded: 1988
€9,025,728
18,382,340
Website: http://www.curasan.de
Address: curasan AG
Lindigstrasse 4,
Kleinostheim,
Bavaria, 63801,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
XTRA CUR Bearer Shares XETRA Trading Platform DE EUR 20. Jul 2000
DB CUR Bearer Shares Deutsche Boerse AG DE EUR 20. Jul 2000
LSE 0OQM Bearer Shares London Stock Exchange GB EUR 20. Jul 2000
Number of employees
Current staff
Staff numbers
38
curasan employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 20:46
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/03/26
Last earnings filing: 2018/08/23
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.